Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Neurobiol Dis. 2018 Jun 23;126:47–61. doi: 10.1016/j.nbd.2018.05.011

Figure 6. Roscovitine, a CDK5 inhibitor, and MK-2206, a pan-AKT inhibitor, promote axon function recovery following OGD.

Figure 6.

Pre-treatment with Roscovitine (5 μM) (Roscovitine, Blue; A and B) applied before OGD promoted a consistent and sustained CAP area recovery. Pre-treatment with MK-2206 (5 μM) (MK-2206, Maroon C and D) applied before OGD promoted a consistent and sustained CAP area recovery. ** p < 0.01, unpaired Student’s two-tailed t-test.